Our results introduce new potential therapeutic targets for AGS, suggesting that a cocktail therapy targeting cGAS, STING, and IFNAR might be suitable for slowing AGS progression in patients. This evidence concerns the gene STING1 and Aicardi-Goutieres syndrome.